Energizing Progress: Syros Announces Inducement Grants in Accordance with Nasdaq Listing Rule 5635(c)(4) on September 7, 2023

Unlocking Potential: Syros Pharmaceuticals Empowers New Talent with Rewarding Stock Grants

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Syros Pharmaceuticals (NASDAQ:SYRS), a pioneering biopharmaceutical company dedicated to redefining the forefront of hematologic malignancy treatment, has announced a significant milestone. The company has granted restricted stock unit (RSU) awards, totaling 20,650 shares of Syros common stock, to welcome two exceptional new team members who have embarked on a transformative journey with Syros. These RSUs symbolize a substantial commitment to fostering talent, in strict adherence to Nasdaq Listing Rule 5635(c)(4).

Conferred on September 1, 2023, these awards come alive with promise. They vest in quarters, with the first quarter maturing on August 31, 2024, and each subsequent quarter marking another milestone, all contingent upon the unwavering dedication of these individuals to Syros. These coveted awards are governed by the terms and conditions outlined in a restricted stock unit agreement, all part of Syros’ forward-thinking 2022 Inducement Stock Incentive Plan.

About Syros Pharmaceuticals

Syros is on a mission to redefine the landscape of hematologic malignancy treatment. With an unwavering commitment to delivering innovative solutions, we aim to revolutionize the frontline care of patients facing blood disorders that have resisted conventional targeted approaches.

Our journey is marked by the relentless pursuit of excellence, exemplified by our robust late-stage clinical pipeline. One of our noteworthy endeavors is tamibarotene, an oral selective RARĪ± agonist designed to combat higher-risk myelodysplastic syndrome and acute myeloid leukemia with RARA gene overexpression. Additionally, we are forging ahead with SY-2101, an ingenious oral form of arsenic trioxide, set to transform the treatment of acute promyelocytic leukemia.

But we don’t stop there. Syros is actively exploring opportunities for SY-5609, a potent and highly selective CDK7 inhibitor with advanced clinical-stage development, poised to make a profound impact on select solid tumors. Our commitment extends to a multitude of preclinical programs in oncology, propelling us towards a future where cancer is no longer an insurmountable challenge.

Leave a Comment